Literature DB >> 856727

[In vitro susceptibility of bacteroidaceae to cefoxitin and cephalothin (author's transl)].

H Werner, R Firsching, C Krasemann.   

Abstract

The activity of the new cephamycin C derivatives cefoxitin against 102 clinical isolates of Bacteroidaceae (95 Bacteroides strains and 7 Fusobacterium-Sphaerophorus cultures) was determined by tube dilution and standardized agar diffusion tests and compared to that of cephalothin. Cefoxitin was more active than cephalothin against 56 Bacteroides fragilis strains, 19 Bacteroides thetaiota-omicron strains and two Bacteroides splanchnicus strains. The difference seemed less pronounced with five Bacteroides vulgatus and four Bacteroides variabilis cultures. Three Bacteroides melaninogenicus and six Bacteroides oralis strains displayed similar sensitivity to both cephalosporins. At concentrations of 32 microng/ml or less, cefoxitin inhibited 91% and cephalothin 33% of the Bacteroides strains. Two strains of Sphaerophorus varius were likewise much more sensitive to cefoxitin than to cephalothin (MIC values 8 micron8/ml of cefoxitin and 256 microng/ml of cephalothin). Three other Sphaerophorus strains (the species necrophorus and freundii/mortiferum) and two of Fusobacterium fusiforme (Fusobacterium nucleatum) strains were very similar in their susceptibility to both cephalosporins. Statistical analysis of the relationship between MIC and zone size diameter showed relatively high correlation coefficients for cefoxitin and cephalothin (r=-0.741 and r=-0.703 respectively).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856727     DOI: 10.1007/BF01639103

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Susceptibility of anaerobes to cefoxitin and other cephalosporins.

Authors:  F P Tally; N V Jacobus; J G Bartlett; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

2.  Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology.

Authors:  W Brumfitt; J Kosmidis; J M Hamilton-Miller; J N Gilchrist
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

Review 3.  [Infections caused by gramnegative anaerobic bacteria].

Authors:  H Werner
Journal:  Med Klin       Date:  1975-11-21

4.  In vitro evaluation of cefoxitin and cefamandole.

Authors:  H G Adams; G A Stilwell; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

5.  Susceptibility of Anaerobic bacteria to carbenicillin, cefoxitin, and related drugs.

Authors:  V L Sutter; S M Finegold
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

6.  Beta-lactamase activity in anaerobic bacteria.

Authors:  A E Weinrich; V E Del bene
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

7.  [Propionate negative saccharolytic bacteroides strains (B. oralis)-occurrence, identification, antimicrobial susceptibility and serological behaviour (author's transl)].

Authors:  H Werner; H Kunstek-Santos; C Lohner; W Schöps; H J Schmitz; H H Karbe
Journal:  Zentralbl Bakteriol Orig A       Date:  1977-04

8.  Cefoxitin, a new semi-synthetic cephamycin: an in-vitro and in-vivo comparison with cephalothin.

Authors:  J Kosmidis; J M Hamilton-Miller; J N Gilchrist; D W Kerry; W Brumfitt
Journal:  Br Med J       Date:  1973-12-15

9.  [Susceptibility to Thiamphenicol and Chloramphenicol of Anaerobic Bacteria (author's transl)].

Authors:  H Werner; C Krasemann; W Gorniak; A Hermann; J Ungerechts
Journal:  Zentralbl Bakteriol Orig A       Date:  1977

10.  Cephamycins, a new family of beta-lactam antibiotics: antibacterial activity and resistance to beta-lactamase degradation.

Authors:  D R Daoust; H R Onishi; H Wallick; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

View more
  1 in total

Review 1.  Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.